Royal Bank of Canada lifted its holdings in Fresenius Medical Care AG & Co. KGaA (NYSE:FMS – Free Report) by 479.2% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 216,861 shares of the company’s stock after purchasing an additional 179,418 shares during the quarter. Royal Bank of Canada’s holdings in Fresenius Medical Care AG & Co. KGaA were worth $4,893,000 as of its most recent SEC filing.
A number of other large investors have also bought and sold shares of FMS. Brooklyn Investment Group raised its holdings in Fresenius Medical Care AG & Co. KGaA by 5.4% during the 4th quarter. Brooklyn Investment Group now owns 8,860 shares of the company’s stock worth $212,000 after buying an additional 450 shares during the period. Advisors Preferred LLC boosted its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 6.1% in the first quarter. Advisors Preferred LLC now owns 10,226 shares of the company’s stock valued at $231,000 after buying an additional 589 shares during the period. Hantz Financial Services Inc. boosted its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 10.5% in the fourth quarter. Hantz Financial Services Inc. now owns 7,370 shares of the company’s stock valued at $176,000 after buying an additional 699 shares during the period. Fifth Third Bancorp boosted its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 4.0% in the fourth quarter. Fifth Third Bancorp now owns 18,766 shares of the company’s stock valued at $447,000 after buying an additional 726 shares during the period. Finally, Arax Advisory Partners increased its position in shares of Fresenius Medical Care AG & Co. KGaA by 121.6% during the fourth quarter. Arax Advisory Partners now owns 1,613 shares of the company’s stock worth $38,000 after acquiring an additional 885 shares in the last quarter. 8.37% of the stock is owned by institutional investors.
Fresenius Medical Care AG & Co. KGaA Trading Down 0.7%
NYSE FMS opened at $23.71 on Thursday. Fresenius Medical Care AG & Co. KGaA has a 12 month low of $20.02 and a 12 month high of $27.64. The company has a current ratio of 1.07, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. The stock has a 50 day moving average of $23.78 and a 200-day moving average of $23.07. The company has a market cap of $12.74 billion, a PE ratio of 12.28, a PEG ratio of 4.43 and a beta of 0.77.
Analysts Set New Price Targets
A number of equities research analysts recently commented on FMS shares. Morgan Stanley restated an “underweight” rating on shares of Fresenius Medical Care AG & Co. KGaA in a report on Wednesday, May 6th. Truist Financial set a $25.00 target price on Fresenius Medical Care AG & Co. KGaA in a report on Wednesday, August 5th. Sanford C. Bernstein lifted their price target on Fresenius Medical Care AG & Co. KGaA from $25.50 to $25.80 and gave the company a “market perform” rating in a research note on Thursday, August 6th. Weiss Ratings restated a “hold (c)” rating on shares of Fresenius Medical Care AG & Co. KGaA in a report on Tuesday, August 4th. Finally, Zacks Research raised Fresenius Medical Care AG & Co. KGaA from a “strong sell” rating to a “hold” rating in a research report on Monday, July 6th. Six analysts have rated the stock with a Hold rating and five have issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Reduce” and an average target price of $23.57.
View Our Latest Analysis on FMS
Fresenius Medical Care AG & Co. KGaA Company Profile
Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.
In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high‐flux dialyzers and bloodlines.
Featured Articles
- Five stocks we like better than Fresenius Medical Care AG & Co. KGaA
- GE Vernova’s AI Power Boom Faces a Profit Test
- Cardinal Health Earnings: Can Perfection Get Priced In Twice?
- Nebius’ Q2 Beat Shows the AI Bottleneck Is Capacity, Not Demand
- Legacy Jet Builders Stall While Embraer Accelerates to New Highs
Want to see what other hedge funds are holding FMS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Fresenius Medical Care AG & Co. KGaA (NYSE:FMS – Free Report).
Receive News & Ratings for Fresenius Medical Care AG & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.
